Title:
MUTANT CTLA4 GENE TRANSFECTED T CELL AND COMPOSITION INCLUDING SAME FOR ANTICANCER IMMUNOTHERAPY
Document Type and Number:
WIPO Patent Application WO/2013/062365
Kind Code:
A3
Abstract:
The present invention relates to a transformed T-cell for T-cell therapy, and a composition including same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the removal of an intracellular signaling domain of CTLA4 or PD1, which is a surface immune tolerance-induced receptor for a T-cell surface, and by the transfection of a gene for coding a CTLA4-CD28 chimera protein or PD1-CD28 chimera protein to which an intracellular activation transduction domain of CD28, which is T-cell activation surface protein, is bound. The T-cell, to which the gene for coding the CTLA4-CD28 chimera protein or PD1-CD28 chimera protein is transected, can solve the problem of impeded therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction of CD28 to induce the activation of T-cells. Also, the activation of CTLA4 or PD1 is inhibited only in cancer cell-specified T-cells, so that it is possible to minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation which may occur in the case where a non-specific CTLA4 or PD1 antagonist is used - for example, a typical anti-CTLA4 antibody.
Inventors:
CHOI KYUNGHO (KR)
SHIN JAEHUN (KR)
LEE SANG-JIN (KR)
SHIN JAEHUN (KR)
LEE SANG-JIN (KR)
Application Number:
PCT/KR2012/008878
Publication Date:
June 20, 2013
Filing Date:
October 26, 2012
Export Citation:
Assignee:
NAT CANCER CT (KR)
International Classes:
C07K19/00; A61P35/00; C12N15/62; C12N15/86
Foreign References:
| US6090914A | 2000-07-18 |
Other References:
JENA, B. ET AL.: "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", BLOOD, vol. 116, no. 7, 3 May 2010 (2010-05-03), pages 1035 - 1044, XP055021403, DOI: doi:10.1182/blood-2010-01-043737
CARTELLIERI, M. ET AL.: "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 2010, 2010, pages 13
SHIN, J.H. ET AL.: "Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models", BLOOD, vol. 119, no. 24, 26 April 2012 (2012-04-26), pages 5678 - 87, XP002743489, DOI: doi:10.1182/blood-2011-09-380519
CARTELLIERI, M. ET AL.: "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 2010, 2010, pages 13
SHIN, J.H. ET AL.: "Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models", BLOOD, vol. 119, no. 24, 26 April 2012 (2012-04-26), pages 5678 - 87, XP002743489, DOI: doi:10.1182/blood-2011-09-380519
Attorney, Agent or Firm:
LEE, Won Hee (642-16 Yoksam-dong, Kangnam-ku, Seoul 135-080, KR)
Download PDF:
Claims: